Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it will rebound. Shorts still have to cover,
Yeah well can it rebound regardless? We sit at no bid again
My assumption is as same yours truly it's over for ARIOQ. Why don't you release your 3 findings now maybe I'll feel a little better.
That was fast ugh
MYFT .0004 now #1 on IHUB low float with active freight company website.
http://www.myfreightworld.com/
You bet he is! $ARIOQ
Is sporty still on the ARIOQ train he took quite a beating this weekend? Untrue or not
Don't worry Sporty. Its Booooom Time
ARIOQ
$PMCB Austrianova’s former Chief Scientist, Lilli Brandtner, features in an article about using Austrianova’s cell encapsulation technology to treat diabetes. Dr Brandtner is working together with Austrianova, PharmaCyte Inc. and other partners as part of PharmaCyte’s International Diabetes Consortium
http://themavorarlberg.at/made-in-vorarlberg/diabetes-heilen
Translation -
Cure Diabetes !
With this ambitious target is currently employs a team of researchers from around the world in a unique project . It is headed by the Vorarlberg scientist Dr. Eva Maria ( Lilli ) Brandtner from the molecular biology laboratory VIVIT in Dornbirn . Together they tried to protect insulin-producing cells from an immune attack to transplant - thereby curing type 1 diabetes would be possible to even have no intact insulin producing cells more and therefore repeatedly have to rely on insulin injections daily . Brandtner are in the " Long Night of Research " on April 22, an exclusive insight into the EU-funded project .
I can't wait until you give us the goods....I can't even go on the ARIOQ board, it's so filled with garbage.
$ARIOQ
I can't wait until you give us the goods....I can't even go on the ARIOQ board, it's so filled with garbage.
$ARIOQ
They are probably all on a conference call making sure they get the new story down pat.
So can we hold the uptrend or do you think they stirred enough doubt to put a damper on that? They went full time this weekend here and everywhere else
I HAVE EXPOSED THE DD FRAUD AND RESEARCH TEAM FINALLY AS THE SHORTS THEY ARE:
Members are posting fictitious information with bogus links and they just banned me from their board. They are posting intentionally erroneous links and spreading mis-information. They have been officially outed as the shorts we have long suspected them of.
SGBY had their 10Q on Friday, will get noticed very shortly, some DD ,
The Company generated $275,330 in revenue for the six months ended March 31, 2016 as compared to $10,412 for the six months ended March 31, 2015. A majority of the increase, $185,260, was a direct result of the consulting services provided to clients assisting with licensing and compliance services. $79,657 was attributed to the acquisition of CR Labs.
On September 17, 2015, Signal Bay, Inc. (the “Company”) entered into an Agreement for Share Exchange (the “Agreement”) with CR Labs, Inc., an Oregon corporation (“CRLB”) and CRLB’s existing shareholders (“CRLB Shareholders”). Pursuant to the Agreement, the Company acquired 80% of CRLB’s issued and outstanding common stock (560,000 shares) from the CRLB Shareholders in exchange for 40,000,000 newly issued restricted shares of the Company, to be issued pro rata the CRLB Shareholders. Pursuant to the Agreement, closing occurred no later than September 18, 2015.
So let's see...we bought CR Labs for 40 mm restricted shares of the company, and already gave us 79,657 $ in revenues. What would you expect from Oregon Analytical and Kenevir Research knowing we paid millions for them???
This is for Oregon Analytical:
"Article IV. PURCHASE PRICE
Section 4.01 Purchase Price. The purchase price for the Assets (the "Purchase Price") will be:
(a)
$972,500.00 for all Assets other than Inventory; and
(b)
The assumption by the Buyer of:"
For Kenevir Research even more...
And LOTS of things coming for the summer:
Signal Bay Services was formed on January 25, 2015, as the management services division of Signal Bay. Currently, Signal Bay Services has one contract with Libra Wellness Services, LLC with anticipated engagement commencing in August 2016.
And Don't forget about California!!!
$$SGBY
I'm not in this to make $2650. Based on the massive volume on Friday and the ginormous swarm of bashers on the ARIOQ board today, this thing is going much higher.
They are certainly not posting there to "save" unsuspecting traders from losing money. In fact, they are there to make money for themselves at the expense of those they are "trying" to save.
$PMCB PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.
According to the American Cancer Society's cancer statistics for 2016, pancreatic cancer is the third leading cause of cancer-related deaths in the United States, and it's one of the few cancers for which survival has not improved substantially over nearly 40 years. But help could be on the way. After PharmaCyte announced last week that the live-cell encapsulation facility where its Cell-in-a-Box® capsules are produced is now current Good Manufacturing Practices or cGMP-compliant, the company cleared what was a major milestone on the way to a clinical trial and is now closer than ever to taking on the challenge of improving the lives of pancreatic cancer patients.
These are truly exciting times at PharmaCyte, and with the cell encapsulation facility now cGMP-compliant, the company can set its sights on first requesting a pre-IND (Investigational New Drug application) meeting with the FDA to discuss the design of its upcoming clinical trial.
This pre-IND meeting will be crucial to developing a relationship with the FDA and getting the necessary answers and guidance moving forward that will allow PharmaCyte to submit its formal IND to the FDA. The pre-IND meeting and the IND submission to the FDA are the next two major milestones for PharmaCyte and its investors.
With the encapsulation facility now ready for the production of clinical trial material, let's look at the trial design that PharmaCyte has announced for its Phase 2b clinical trial:
PharmaCyte's pancreatic cancer therapy consists of placing microcapsules containing genetically engineered live cells near the blood supply to the pancreas. The cancer prodrug ifosfamide is then given at one-third the normal dose. When the blood carries the chemotherapy drug to where the capsules have been placed, activation of the drug takes place right at the source of the cancer instead of in the patient's liver, which eliminates any side effects in these patients.
The trial will be a multi-site trial held in both the United States and Europe. It will also be an open-label trial in which the patients will be randomized between two study groups. The trial has been designed to meet a clear unmet medical need that exists for a particular group of pancreatic cancer patients.
The randomization ratio of patients between the two study groups will be 1:1 (an equal number of patients will be randomly assigned to the capecitabine + radiation group and the PharmaCyte pancreatic cancer therapy group).
Only patients who have locally advanced, non-metastatic, inoperable cancer and whose tumors no longer respond after 4-6 months of treatment with either the widely used Abraxane® + gemcitabine combination therapy or FOLFIRINOX, will be eligible for the trial. These patients are usually treated with the combination of the chemotherapy drug capecitabine + radiation, but this treatment is only marginally effective and is quite toxic for the patients.
Study sites under consideration in the U.S. include the Mayo Clinic in Scottsdale, Arizona, the Beth Israel Deaconess Cancer Center in Boston, the Dana-Farber Cancer Institute also in Boston, the Baylor Cancer Center in Dallas, Texas, Cedars-Sinai Medical Center in Los Angeles, as well as sites in Germany and Spain.
It is believed that 84 patients will be required to complete the study, although fewer may be required based upon the data developed during the trial.
Unlike in earlier clinical trials using PharmaCyte's pancreatic cancer therapy where patients received only two cycles of therapy with ifosfamide, multiple cycles of ifosfamide will be given to those being treated with PharmaCyte's pancreatic cancer therapy. This will continue until the patients' tumors no longer respond to PharmaCyte's therapy or until treatment-related toxicity accumulates to unacceptable levels.
And the best news of all for investors heading into these exciting times is that PharmaCyte has been awarded the Orphan Drug designation by both the U.S. FDA and the European Medicines Agency (EMA). This designation means that the company's pancreatic cancer therapy will have complete protection and market exclusivity for years to come. After PharmaCyte's therapy is approved for marketing by these two regulatory agencies, they will enjoy 7 years of market exclusivity in the United States and 10 years of protection in the European Union.
PharmaCyte's CEO also recently stated that the company's pancreatic cancer therapy qualifies for 12 years of data exclusivity because it is considered a "biologic" as outlined by the Biologics Price Competition and Innovation Act (BPCIA).
So, as the company marches headlong into a Phase 2b clinical trial in the U.S. and Europe with a built in "hard stop" about half way through the trial to review the data, there is no better time than the present to get excited about this small biotechnology company and what could very well be a significant contribution to the treatment of pancreatic cancer.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
You as well Bean.
Can't wait! Have a great weekend Sporty!
Great, you are already ahead $2650.00. CONGRAT$$$ More coming.
Ended the day with 26.5 million ARIOQ 0002s in my account.
Will sit back and watch now.
LOL - I am from Brasil man you are hurting my feeling's
that was a funny one Sporty
they are like Zyka carrying mosquitoes.
I got one those chasing me around - lol
Shorts geting desperate now posting false information and hitting the bid for small amounts.
To be expected I guess.
ARIOQ is ROP, not RIP.
$ARIOQ running 2's out of town
.0064s back hitting, .007s for power hour? SVTE
ARIOQ 2's R a steal when Q get drop out it will be @0.001 $$$$$$$$$$$$$$$
Forward looking catalyst, and TREMENDOUS value down here.
No doubt about it $ARIOQ great run ahead of us $$$$$$$$$$$
Soon to be 3333333333333333's
$ARIOQ 2's taking OFF !!
!! Smart Money Group Loading 100 Million @0002
Watch it folks fireworks $$$$$$$$$$$$$
ARIOQ--HUGE ALERT
We have ascertained information via current filings that make this BK play very lucrative. The Q comes off June 23rd. Was NO bid this morning now at .0002, will drop a zero by the time the q comes off.
BZTG Update
Yesterday June 2, we received a list of questions from Finra.
We are completing that information over the weekend and it will be filed Monday.
On the business front, HEFFX is still building out the new version of the trading platform, the company has appointed a new CEO to the Fashion Incubator, LTN is still being rebuilt and we will be opening the doors to partners in different parts of the world in July.
The name change has been effected everywhere (SoS, Bloomberg,Reuters, Transfer Agent) but we are still awaiting the change to reflect on OTC Markets.
The Finra application is being handled by a very competent and experienced Lawyer, like all those following we are checking the Daily List often, at this point everyone will see the change come through at the same time.
It is very exciting and frustrating, but there is nothing more we can do but wait.
At the business end HEFFX is Beta testing a new trading platform, has rebuilt Live Trading News for the Mobile Device market and is seeing strong growth in Private Equity.
Private Equity will see no less than 4 to 6 listing in 2016.
Business has expanded from South East Asia and the Middle East to Central and South America.
DIGX up 50%. Super thin L2. great news few days ago and still under the radar. Something is coming.
Here's news from few days ago....AS reduction, no toxic debt.
I encourage all to read this***ISBG
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123063540
Hey Sporty - what's up with KGNX?
No news yet and the board is mess, nothing but nonsensical pumpers and bashers.
Thanks
CGRA is providing a loading opportunity under a penny today.
EVTI 0001 from the ground up IMO 0003 X 0004 next week
You might wanna do some DD on $NSEH asap
Hey Sporty Norty. You might want to check out ARIOQ. The Bankruptcy Plan has been approved and the Q is about to fall soon. Plus its at 0.0001. Please let your group know. IMO this is a great opportunity. Just thought I would let you and your group know to take a look. Thanks have a great day Sporty.
$TPNI --->>> Heading to BullsLand this june
!!!
with a target of .0035
& Las vegas june convention coming up #News#Deals
InDaMaking - TPNI @ NFPA Expo in Vegas next month listed under OFFICIAL CONTRACTORS as Lead Retrieval & Registration for the event.
2016ceFullServiceKit.pdf
Followers
|
363
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
14043
|
Created
|
04/20/14
|
Type
|
Free
|
Moderators sharky OptimusPrime |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |